Market Place
Sourcing Support
Inotrem Reaches Agreement with the FDA for a Phase 3 Trial for Nangibotide
08 Jan 2024 //
BUSINESSWIRE
Inotrem Receives Funding From the Crohn’s & Colitis Foundation Ventures Program
06 Nov 2023 //
BUSINESSWIRE
Inotrem Announces Publication of Two Key Articles on Nangibotide PII Programs
01 Jun 2023 //
BUSINESSWIRE
Inotrem Receives Funding From the Crohn’s & Colitis Foundation for IBD
09 Jan 2023 //
BUSINESSWIRE
Inotrem Announces That the PII Study for Treatment of COVID-19 Meets Endpoints
25 Oct 2022 //
BUSINESSWIRE
Inotrem posts 2nd data drop of the month, this time for COVID
25 Oct 2022 //
FIERCEBIOTECH
Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial
13 Oct 2022 //
BUSINESSWIRE
Inotrem sparks hope with new phase 2b data
13 Oct 2022 //
FIERCEBIOTECH
Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement
14 Apr 2022 //
BUSINESSWIRE
Inotrem Adds a New Strategic Asset to Its Immunotherapy Anti-TREM-1 Pipeline
23 Jun 2021 //
BUSINESSWIRE
Inotrem Announces Provided Update of Phase IIB ASTONISH Trial
10 Jun 2021 //
BIOSPACE
Inotrem Reports Interim Futility Analysis for Its Phase IIB ASTONISH Trial
10 Jun 2021 //
BUSINESSWIRE
Inotrem’s COVID-19 Phase IIa Trial Declared “National Priority Research”
23 Dec 2020 //
BIOSPACE
Inotrem’s COVID-19 Phase IIa Trial Declared “National Priority Research”
23 Dec 2020 //
BIOSPACE
Inotrem announces Data Monitoring Committee (DMC) recommends of Phase IIa study
21 Dec 2020 //
BUSINESSWIRE
Inotrem to initiate Phase IIa study of nangibotide for Covid-19
23 Jul 2020 //
CLINICALTRIALSARENA
Inotrem Receives Clearance From French, Belgian And US Authorities to Launch
22 Jul 2020 //
BUSINESSWIRE
Inotrem Receives Clearance From French & US Authorities to Launch a PhII Trial
22 Jul 2020 //
BUSINESSWIRE
IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets
07 May 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.